PIONEER WP2 Patient reported outcomes in advanced prostate cancer.
Research type
Research Study
Full title
PIONEER WP2 What outcomes are important for patients with advanced prostate cancer? An interview study protocol.
IRAS ID
266863
Contact name
Mieke Van Hemelrijck
Contact email
Sponsor organisation
King's College London
Duration of Study in the UK
0 years, 10 months, 1 days
Research summary
Prostate cancer is the most common non cutaneous cancer affecting men worldwide. It is becoming increasingly challenging to compare and develop existing and emerging literature as a variety of different measures are used between investigations. Consequently, it is difficult to develop guidelines, determine outcome measures and compare treatments. Additionally, men’s voice is often missing from clinician determined outcome measures and this is particularly relevant in the case of advanced prostate cancer where palliative care is in place and more likely to require patient input on appropriate measures.
To overcome this, the international PIONEER consortium has been working to develop standardised Core Outcome Sets (COS) which are “agreed standardised collection of outcomes which should be measured and reported, as a minimum, in all trials for a specific clinical area” for all types of prostate cancer. Previous work has been carried out to inform, develop and construct COS for localised prostate cancer but no holistic, patient care driven outcome sets currently exist for advanced prostate cancer.
Therefore, a detailed investigation exploring the thoughts, feelings and experiences of men with advanced prostate cancer is necessary to accurately inform the development of an advanced prostate cancer COS.
REC name
London - Stanmore Research Ethics Committee
REC reference
19/LO/1536
Date of REC Opinion
23 Oct 2019
REC opinion
Further Information Favourable Opinion